A Phase II Investigator Sponsored Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Biliary cancer; Biliary tract disorders; Gallbladder cancer
- Focus Therapeutic Use
- 05 Feb 2018 Planned End Date changed from 31 Oct 2019 to 31 Oct 2020.
- 21 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 19 Sep 2016 Status changed from not yet recruiting to recruiting.